Close
Find your Coloplast country website
RSS
Need to always be updated?
Sign up to our RSS feed

 


 

.

News and press releases

  • Press release
16 Aug 2017

Coloplast delivers satisfactory Q3 result

Coloplast delivered 8% organic revenue growth in the Q3 2016/17 period. Revenue in DKK was up by 6% to DKK 3,912m. The results were in line with the company’s expectations.

Read news story

Coloplast delivered organic growth of 8% in the third quarter of the 2016/17 financial year. When measured in Danish kroner, revenue was up by 6% to DKK 3,912m.

Reported Q3 revenue was adversely affected by a DKK 90m one-off revenue adjustment made after Coloplast identified incorrect management of contractual obligations relating to an agreement with the U.S. Department of Veterans Affairs for the period 2009-2017. The matter relates to continence care products and has not affected the organic growth rate for the reporting period. Coloplast has recently renewed the contract with the U.S. Department of Veterans Affairs and the company has now opened a dialogue with the U.S. Department of Veterans Affairs in order to resolve the matter.

EBIT was up by 9% at constant exchange rates, adjusted for the one-off revenue adjustment for the U.S. Department of Veterans Affairs for, and up by 4% in DKK to DKK 3,705m. The EBIT margin was at 33% at constant exchange rates and before the one-off adjustment, which was in line with last year’s percentage.

Q3 organic growth rates by business area: Ostomy Care 7%, Continence Care 10%, Urology Care 10%, and Wound & Skin Care 1%.

By geographies, the European markets contributed 4% growth. “Other established markets” and Emerging Markets both delivered 14% revenue growth.

-        “We’re delivering a satisfactory Q3 result with many of our major markets performing well, including the UK and the USA. The integration of Comfort Medical in the USA continues to progress to plan, and our US Chronic Care business reported double-digit organic sales growth in the third quarter. Also, our Emerging Markets business delivered 14% organic growth in the third quarter, driven by strong growth momentum in China and Russia,” said Coloplast CEO Lars Rasmussen. 

-        “Pricing reforms in Greece and France had a negative impact on sales growth in the Wound and Skin Care business in the third quarter, but the effect was offset by a stronger momentum for the Wound Care business in China and for the Skin Care business in the USA,” said Mr Rasmussen.

 

New products to drive growth

Coloplast continues to launch new products in all core markets, including the SpeediCath® Flex catheter, which is now available in fourteen markets. Feedback on the product has been very positive.

In the Ostomy Care business, Coloplast is now relaunching the SenSura® Mio Convex, after having expanded production capacity in Hungary to accommodate market demand. The relaunch is progressing to plan.

 

Financial guidance for 2016/17

We continue to expect organic revenue growth of 7–8% at constant exchange rates. The guidance for organic revenue growth has not been affected by the one-off revenue adjustment of DKK 90m. The guidance for reported revenue growth is revised to 6% in DKK instead of as previously 7–8%, due to the one-off revenue adjustment of DKK 90m and to exchange rate developments with especially the depreciation of the USD and GBP having a negative impact. 

The EBIT margin guidance remains at 33–34% at constant exchange rates. The EBIT margin guidance at constant exchange rates includes the one-off revenue adjustment of DKK 90m. The reported EBIT margin guidance in DKK is revised to about 32% instead of as previously about 33%, due to the one-off revenue adjustment of DKK 90m and to exchange rate developments with especially the depreciation of the USD and GBP having a negative impact. 

 

CONTACTS

Dennis Kaysen

Director, Corporate Communications

+45 49 11 26 08

dkdk@coloplast.com

 

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

  • Press release
3 May 2017

Coloplast delivers satisfactory Q2 result

Coloplast delivered 8% growth when measured in DKK and 7% organic revenue growth, as well as an EBIT margin of 32% at constant exchange rates in the second quarter of its financial year. The results are in line with the company’s expectations.

Read news story

In the second quarter of the 2016/17 financial year, Coloplast delivered 8% growth measured in Danish kroner corresponding to DKK 3,881m, and 7% organic revenue growth. EBIT was up by 7% to DKK 1,246m and net profit for the Q2 reporting period was up by 2% to DKK 931m.

Organic growth rates by business area were: Ostomy Care 7%, Continence Care 8%, Urology Care 14%, and Wound & Skin Care negative 4%.

Geographically, the European markets contributed 5% growth with the UK and France as the standouts. Other established markets delivered 8% growth, while Emerging markets delivered 10% growth.

“We’re delivering a satisfactory Q2 result with many of our European markets performing well. In addition, the integration of Comfort Medical in the US is progressing according to plan and our US Chronic Care business reported double-digit sales growth in the second quarter after inventory levels at our large distributors had been normalised in the first quarter. That is having a positive effect on our Ostomy Care and Continence Care businesses, and we expect continued positive sales growth in our US business in the coming quarters. Currency developments continued to have a negative effect on reported sales as well as earnings, while the acquisition of Comfort Medical had a positive effect on reported sales in the quarter,” said Coloplast CEO Lars Rasmussen.

“Sales growth in the Wound and Skin Care business was adversely affected by a very strong performance of the US Skin Care business in the second quarter of last year. On the other hand, the Wound Care business in China reported positive momentum in the second quarter, which we expect will continue in the coming quarters,” said Mr Rasmussen. 

New products to drive growth

Coloplast continues to launch new products in all core markets, including the SpeediCath® Flex catheter and the Biatain® Silicone Sizes & Shapes wound care portfolio. Both products have received very positive feedback.

In the Ostomy Care business, Coloplast is now relaunching the SenSura® Mio Convex, having expanded production capacity in Hungary to accommodate market demand. In addition, the new SenSura® Mio Hospital portfolio will be available in all core markets over the next 12 months, and the Brava® Protective Seal accessory product is now available in 13 countries.

Financial guidance for 2016/17

Coloplast maintains its guidance for organic revenue growth of 7-8% at constant exchange rates and reported growth of 7-8% in DKK. The EBIT margin guidance remains at 33-34% at constant exchange rates and at about 33% in DKK.

 

CONTACTS

Dennis Kaysen

Director, Corporate Communications

+45 49 11 26 08

dkdk@coloplast.com

 

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

  • Press release
3 Apr 2017

Coloplast wins Red Dot design award for high quality design

Coloplast’s Biatain Silicone® sizes & shapes has been awarded with the Red Dot award; an internationally recognised consumer award that focuses on user experience and aesthetics of products.

Read news story

Since 1954, the Red Dot Award has been a global benchmark for design and innovation focusing on the user experience and aesthetics of a wide range of consumer products. This year, Red Dot received 5500 submissions from 54 countries and all of the products entered were assessed by an independent and international jury of experts.

 

Professor Dr. Peter Zec, founder and CEO of the Red Dot Award: “The Red Dot winners are pursuing the right design strategy. They have recognised that good design and economic success go hand in hand. The award by the critical Red Dot jury documents their high design quality and is indicative of their successful design policy.”

 

Coloplast Wound Care’s entry of the Biatain Silicone sizes & shapes, has been measured successfully against innovative design across various industries and awarded a Red Dot Award as one of the globally most outstanding product designs in 2017. 

 

The Biatain Silicone products are soft, flexible, absorbent foam dressings with a silicone adhesive used for treating chronic and acute wounds. Biatain Silicone sizes & shapes was launched in 2016 as an extension to the Biatain Silicone product range with eight new sizes and shapes designed to conform to the different areas of the body. 

The new products have been launched across 14 markets globally.

 

Accelerating Wound Care growth

“We are very proud and pleased to have won a Red Dot Award, which is an internationally recognised quality label for great design. The Biatain Silicone sizes & shapes products are designed according to the Coloplast Design DNA, meaning that our users will experience not only a product which provides superior absorption and faster healing, but also an intuitive and non-medical looking product with a life-style oriented design” says Nicolai Buhl, Senior Vice President in Coloplast Wound & Skin Care.

 

“The launch of the Biatain Silicone range has accelerated the Coloplast Wound Care growth in recent years, and with the extension of the range, we believe we can accelerate growth even further”, Nicolai ends.

 

In July 2017, the design team behind Biatain Silicone Sizes & Shapes are going to Essen, Germany to receive the award at the Red Dot Gala.

 

 

 

 

CONTACTS

Dennis Kaysen

Director, Corporate Communications

+45 4911 2608

dkdk@coloplast.com

 

Ellen Bjurgert

Investor Relations Director

+45 4911 3376

dkebj@coloplast.com

 

  • Press release
1 Feb 2017

Coloplast delivers satisfactory Q1 interim results in line with expectations

In Q1, Coloplast delivered organic revenue growth of 6% and an EBIT margin of 33% at constant exchange rates. The results are in line with expectations.

Read news story

Coloplast delivered organic growth of 6% in the first three months of the 2016/17financial year, increasing revenue measured in Danish kroner by 3% to DKK 3,755m.EBIT increased by 3% to reach DKK 1,226m, while the profit for the period was upby 15% to DKK 946m.

 

Coloplast continued to generate growth in all business areas in the first quarter,delivering organic growth in Ostomy Care at 6%, Continence Care at 5%, Wound &Skin Care at 5% and Urology Care at 8%.

 

In Continence Care, Coloplast recently launched a new flexible catheter for men, theSpeediCath Flex. The product is now on the market in 11 countries. In addition, inWound & Skin Care, the Biatain Silicone Sizes & Shapes product portfolio had beenlaunched in eight countries on 1 January. Both launches have received very positivefeedback from users and healthcare professionals.

 

Geographically, Europe was the main growth driver overall, delivering 6% organicgrowth, with sales growth in the UK and France standing out. Other developedmarkets produced 4% growth, while Emerging Markets contributed 7%.

 

“We delivered satisfactory results in the first quarter of the year, supported by aparticularly strong performance of our European business. Growth in the US wasaffected by inventory reductions of large distributors. Inventory levels are nowback to normal, and we expect this to drive favourable sales growthdevelopments in the coming quarters,” says Lars Rasmussen, CEO of Coloplast.

 

In a move to support the overall ambition of bringing innovative products andservices to the US market, Coloplast acquired US distributor Comfort Medical inNovember. The acquisition was approved in late December, and the process ofintegrating the company has now been set in motion.

 

Coloplast continues to expect an organic revenue growth of 7-8% at constantexchange rates. Coloplast now expects organic revenue growth of 7-8% in Danishkroner (DKK) following the acquisition of Comfort Medical and developments in theBritish pound and the US dollar. Coloplast continues to expect the EBIT margin to be33-34% at constant exchange rates and about 33% in DKK.

 

 

CONTACTS

Maria Lindeberg

Senior Media Relations Manager

+45 49 11 30 95

dkmalg@coloplast.com

 

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

  • Press release
30 Nov 2016

Coloplast acquires Comfort Medical

Coloplast acquires Comfort Medical, a US direct-to-consumer nationwide dealer of catheters and ostomy supplies, for USD 160m. The acquisition is a continuation of Coloplast’s ambition to bring innovative products and services to the US market.

Read news story

Coloplast has entered into a definitive agreement to acquire Comfort Medical, LLC (Comfort Medical) for a cash consideration of USD 160m equal to approx. DKK 1,120m.

Comfort Medical is a privately owned, US direct-to-consumer Durable Medical Equipment (DME) nationwide dealer of catheters and ostomy supplies founded in Florida in 2010. The acquisition is a continuation of Coloplast’s ambition to bring innovative products and services to the US market.

“The acquisition of Comfort Medical fits very well into our overall consumer ambition for Coloplast in the US, securing continued access to innovative technology for end users. Comfort Medical has a strong patient acquisition model and an efficient and scalable setup in addition to a strong management team with a good cultural fit to Coloplast,” says Lars Rasmussen, Coloplast’s CEO.

Comfort Medical’s business model is based on capturing patients through Direct Response Advertisement and physician referrals. Comfort Medical provides patients with products froma number of different manufacturers including Coloplast. The company is expected to record sales of USD 38m or approx. DKK 270m for the full-year 2016.

“I am excited about the future prospects of our US business and view this acquisition as an additional building block in the implementation of our US strategy,” Lars Rasmussen says.

The transaction is expected to contribute to Coloplast’s long-term growth ambition and is expected to close in the first quarter of 2016/17. The acquisition will, if completed and approved by authorities, lead to a revised financial guidance for the financial year 2016/17:

  • The organic revenue growth guidance of 7-8% is unchanged. The growth in DKK of 5-6% is expected to be 1-2%-points higher.
  • The EBIT margin guidance of 33-34% in constant exchange rates and about 33% in DKK is unchanged.
  • The long-term guidance of 7-9% organic growth p.a. and an EBIT margin expansion of 0.5%-1.0%-points p.a. is unchanged.

 

Media contact:

Maria Lindeberg, Senior Media Relations Manager

Tel. +45 4911 3095

dkmalg@coloplast.com

 

Investors and analysts:

Ellen Bjurgert, Director, Investor Relations

Tel. +45 4911 1800 / +45 4911 3376

dkebj@coloplast.com

  • Press release
29 Nov 2016

Coloplast reaches milestone in South Korea

The government of South Korea will be improving subsidies to the country’s catheter users after the turn of the year, marking a breakthrough for Coloplast’s Continence Care business in the country.

Read news story

Thousands of South Koreans suffering from disorders such as spinal cord injury, multiplesclerosis and Parkinson’s disease will be able to opt for better and more modern catheters next year. Public reimbursement rules in South Korea have been improved, and that is good news to Coloplast, as the company aims to outgrow the market in the Continence Care business area.

An estimated 25,000 users in South Korea who need help emptying their bladder are covered by the public reimbursement scheme in the country, and they will now be able to opt for modern catheters. According to Coloplast CEO Lars Rasmussen, the reimbursement will support the company’s growth opportunities in South Korea.

“This is good news for Coloplast in South Korea and for the users, whose everyday lives will be made easier with the benefits of modern catheters, enabling them to live the life they want to”, says Coloplast CEO Lars Rasmussen.

Previously, South Korea only offered reimbursement to a limited group of users, but the improved access will allow all catheter users covered by the national health insurance access to better products.

Continence Care is Coloplast's second-largest business area, accounting for some 35% of consolidated revenue. Coloplast’s other business areas are Ostomy Care, Wound & Skin Care, and Urology Care. Last year, Coloplast generated revenue of DKK 14.7 billion.

Facts:

  • The new reimbursement rules apply to persons who needs help to empty their bladder due to acquired disability and who are registered with the national health insurance in South Korea. Previously, only patients with Spina Bifida were covered.
  • The reimbursement will improve the quality of life of the users. Instead of reusing their catheters, they can now use a new one each time they need to empty their bladder.
  • The new reimbursement rules take effect on 1 January 2017.
  • Coloplast is represented in over 130 countries and has approximately 10,000 employees.

Contact:

Maria Lindeberg, Senior Media Relations Manager

Tel: + 45 49 11 30 95

dkmalg@coloplast.com

  • Press release
2 Nov 2016

Coloplast delivers full-year results in line with guidance

Revenue for the 2015/16 financial year was up by 7%, with the EBIT margin before special items at 34% at constant exchange rates. In DKK, revenue increased by 6% and the EBIT margin before special items was 33%, the difference mainly being due to GBP currency headwinds. The results were consistent with the guidance provided

Read news story

Coloplast’s products are becoming increasingly popular with users, as reflected in growing sales and the improved earnings for the financial year 2015/2016. Full-year organic sales growth rates were 9% in Ostomy Care, the largest business area, 5% in Continence Care, 9% in Urology Care and 6% in Wound & Skin Care.

European sales were up by 6 % and Coloplast’s homecare company Charter in the UK played a key role in increasing Coloplast’s market share in the country.

“We’ve seen impressive contributions from our European subsidiaries within all business areas, not least in the UK market as Charter continuously performs well, and users increasingly favour our stoma bags, catheters and accessories,” said Coloplast CEO Lars Rasmussen.

Other developed markets produced 6% organic growth, while sales in Emerging Markets were up by 14%. There is a strong underlying demand in the US market, although distributors continued to downscale their inventories which posed a challenge. Growth rates in the US market are expected to improve in the 2016/17 financial year.

Product launches to drive future growth

This fall, Coloplast launched a new flexible catheter for men, the SpeediCath Flex, and a new series of silicone dressings, the Biatain Silicone Sizes & Shapes. Both products are expected to become future growth drivers, just like the Sensura Mio Convex stoma bag.

“I’m pleased with our full-year results. Clearly, users are welcoming the innovative products we’ve developed to make their lives easier. This makes our new product launches all the more exciting to follow, in our efforts to achieve our long-term growth targets,” said Mr Rasmussen.

The full-year EBIT was impacted by a provision of DKK 750m to cover potential settlements and costs in connection with the lawsuits in the United States alleging injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence. More than 90% of the cases are considered settled.

2016/17 guidance

For the 2016/17 financial year, Coloplast expects organic revenue growth of 7-8% at constant exchange rates and of 5-6% in DKK, with the EBIT margin expected at 33-34% at constant exchange rates and at about 33% in DKK.

For more on the full-year 2015/16 financial report, go to http://www.coloplast.com/investor-relations/announcements/2016/ (available shortly)

The Annual Report and the Corporate Responsibility Report will be released later today. For more information, go to http://www.coloplast.com/investor-relations/annual-reports/ and http://www.coloplast.com/about-coloplast/responsibility/policies/

Financial highlights and key ratios (DKKm) 

2015/16 FY 

2014/15 FY 

Change 

Revenue 

14,681 

13,909 

6% 

EBIT before special items 

4,846 

4,535 

7%

EBIT margin before special items (constant exchange rates)

34%

33%

 

EBIT margin before special items (DKK) 

33% 

33% 

 

Special items 

-750 

-3,000 

- 

EBIT  

4,096 

1,535 

>100%

 

Sales performance by business area (DKKm)

2015/16 FY

2014/15 FY

Organic growth

Reported growth

Ostomy Care

5,935

5,567

9%

7%

Continence Care

5,182

5,019

5%

3%

Urology Care

1,497

1,359

9%

10%

Wound & Skin Care

2,067

1,964

6%

5%

 

Financial guidance for 2016/17

 

FY 2015/16 guidance

Guidance (in DKK)

Sales growth

7-8% (organic)

5-6%

EBIT margin

33-34% (at constant exchange rates)

~33%

CAPEX

-

~700

Tax rate

-

~23

 

Press enquiries

Maria Lindeberg

Senior Manager, Media Relations

Tel. +45 4911 3095

dkmalg@coloplast.com

  • News
  • Press release
26 Sep 2016

Coloplast introduces new silicone wound dressings as part of growth ambition

By launching a new series of silicone dressings that conform to the natural contours of the body, Coloplast takes another step towards the goal of doubling the size of its Wound Care business by the 2020/21 financial year. The new series of silicone dressings is scheduled to launch starting in December and will launch in all key markets during 2016/2017.

Read news story

Coloplast is expanding its Biatain Silicone portfolio with eight new wound dressings referred to as Sizes & Shapes. Used for treating chronic wounds, the dressings are shaped to fit a heel, the hollow of the knee, the back of the neck or the shoulder; places where it can be difficult to apply a dressing properly.

 

According to Nicolai Buhl, SVP of Coloplast’s Wound Care business, innovative products such as Sizes & Shapes form an important part of Coloplast’s growth plans.

 

- Our new silicone wound dressings give the competition a run for its money, while giving the users what they want: wound dressings that conform to the body’s natural shape. We’re confident that our new wound dressings, developed by healthcare professionals and shaped by users, will strengthen our position in the global wound care market, because we now have a complete product offering for many different wound types, says Nicolai Buhl.

 

Coloplast’s Wound Care business currently has a global market share of 5–10 percent. The company’s ambition is to grow to 10–15 percent by the 2020/21 financial year.

 

Facts

- The global market for wound care products is estimated at DKK 16–17 billion, and market growth is estimated at 3–5 percent per year.

- Coloplast’s Wound Care Business has a 5–10 percent global market share.

- The new Biatain Silicone Sizes & Shapes series builds on the existing Biatain Silicone portfolio.

 

Read more: Coloplast.com/products/wound/biatain-silicone--fewer-days-with-wounds/

 

Press enquiries

Maria Lindeberg

Senior Media Relations Manager

Tel. +45 4911 3095

dkmalg@coloplast.com

  • News
  • Press release
14 Sep 2016

New flexible catheter part of Coloplast growth plan

This October, Coloplast will be launching a new flexible catheter for men. With this new product, Coloplast now has a complete range of catheters for all users.

Read news story

Coloplast will begin the roll-out of a new flexible male catheter next month.

Scheduled for launch on the company's core markets in October, the new catheter is the latest addition to Coloplast’s innovative product portfolio and adds further fuel to the company’s plans to outperform its competitors in the continence care market.

The current growth rate in the global continence care market is 5 – 6 percent per year, and launching new products like the SpeediCath Flex is Coloplast’s recipe for outgrowing the rest of its competitors on the market.

“Our ambition is to continue to gain market share. To do that we need innovative products like the SpeediCath Flex. It is discreet, hygienic and easy to use,” said Kristian Villumsen, Executive VP of Coloplast’s Chronic Care business, which includes the Continence Care division.

As part of the SpeediCath range of male catheters, the SpeediCath Flex is available in both compact and traditional versions.

“By adding another catheter to our product catalogue, we help make life easier for even more users,” said Mr Villumsen.

Continence Care is Coloplast's second-largest business area, accounting for some 35 percent of consolidated revenue. Coloplast’s other business areas are Ostomy Care, Wound & Skin Care, and Urology Care.

Facts

  • SpeediCath Flex will be rolled out in all major markets in 2016 and 2017.
  • A special feature of the new product is its flexible tip and dry sleeve, which is a protective film that makes catheter insertion easy.

Press enquiries

Maria Lindeberg

Senior Media Relations Manager

Tel. +45 4911 3095

dkmalg@coloplast.com

 

Read more: Coloplast.com/speedicat-flex

  • News
  • Press release
  • News
16 Aug 2016

Coloplast delivers 9M result in line with guidance

Revenue grew by 7% organically to DKK 10,942 million in the 9M 2015/16 period. EBIT was up by 8% to DKK 3,562 million for an EBIT margin of 33%. The results are in line with expectations.

Read news story

All over the world, more and more people living with a stoma are choosing Coloplast’s stoma bags and accessories. As a result, the company’s sales outperformed the market in the first nine months of the financial year. Sales in the Ostomy Care business area grew by 11% in the third quarter and by 9% in the 9M reporting period.

"Our latest ostomy care product, the SenSura Mio Convex is now available in sixteen countries, and feedback from users and healthcare professionals remains highly satisfactory. We now have the complete SenSura Mio portfolio on the market, which has a positive effect on growth in our Ostomy Care business," says Coloplast CEO Lars Rasmussen.

Sales in the Continence Care business grew 5% in the 9M period, mainly driven by disposable Speedicath catheters and Peristeen. Sales in the US market remain challenged as distributors continue to downscale their inventories, but the underlying growth is positive.

The Wound & Skin Care business delivered 7% organic growth. The European market is a positive contributor, while the Wound Care business remains challenged by slowing growth in China. Urology Care sales were up by a satisfactory 8%.

Solid growth in Europe

Coloplast’s sales to the European market were up by 6% in the 9M reporting period and by 8% in the third quarter alone, in part driven by solid growth in the UK market.

"With the UK being our largest single market, I’m very pleased to note that we are again generating strong growth in the UK and that users are happy with our products. We’re winning market share, and that’s very satisfactory," Lars Rasmussen says.

Germany and the Nordic markets also contributed to sales growth. In non-European markets, Argentina, China and Russia were the main contributors.

Maintaining guidance

Coloplast maintains its guidance for the 2015/2016 financial year of 7–8% organic revenue growth at constant exchange rates and now of about 6% in DKK. The EBIT margin is expected to be 33–34% at constant exchange rates and about 33% in DKK.

For more on the Q3 2015/16 interim report, go to www.coloplast.com/investor.  

 

Press enquiries

Maria Lindeberg

Senior Media Relations Manager

Tel. +45 4911 3095

dkmalg@coloplast.com

 

Investors and analysts

Ellen Bjurgert

Investor Relations Manager

Tel. +45 4911 3376

dkebj@coloplast.com

  • Press release
3 May 2016

Coloplast delivers H1 result in line with expectations

Revenue was up by 7% to DKK 7,256 million in H1 2015/16. EBIT was also up by 7% to DKK 2,361 million for an EBIT margin of 33%. The results are in line with the company’s guidance.

Read news story

A growing demand for Coloplast’s ostomy care products among European users produced strong sales and 8% organic growth for the Ostomy Care business in the first six months of the 2015/16 financial year.

“More and more users are choosing our stoma bags and accessories, allowing us to outgrow the market. We’ve also just launched one of our future growth drivers, the Sensura Mio Convex, in fifteen countries, and user feedback has been highly satisfactory,” said Coloplast CEO Lars Rasmussen.

In the regional markets, Coloplast is generating solid sales growth in Europe, and especially Coloplast UK, its largest subsidiary, is a strong contributor to growth in the European business. Charter, Coloplast’s own distribution company in the UK, is also winning market shares.

“UK is currently the stand-out market in Europe, however, countries like France and the Netherlands are also delivering good results, steering our European market in the right direction,” says Mr Rasmussen.

The Wound & Skin Care business delivered 9% organic growth in the reporting period, and Urology Care sales were up by 8%.

Coloplast’s Continence Care business grew by 4%, the weak growth rate being mainly due to amended distributor contracts in the US market. Sales are expected to normalise in the second half of the financial year.

Coloplast maintains its guidance for the 2015/2016 financial year of 7–8% organic revenue growth at constant exchange rates. With GBP and USD weakened against DKK, the company now expects 6–7% growth in DKK instead of previously 7%. The EBIT margin is expected to be 33–34% at constant exchange rates and about 33% in DKK.

For more on the Q2 2015/16 interim report, go to www.coloplast.com/investor

 

Press enquiries

Maria Lindeberg

Senior Manager, Media Relations

Tel. +45 4911 3095

dkmalg@coloplast.com

 

Investors and financial analysts

Ian Christensen

Vice President, Investor Relations

Tel. +45 4911 1301

dkisec@coloplast.com

  • Press release
9 Mar 2016

Coloplast gets breakthrough with continence business in Japan

The Japanese healthcare authorities have decided to improve reimbursement for intermittent catheters. This represents a breakthrough in the Japanese market for Coloplast, who will have an easier time offering the newest and best catheters to people living with incontinence in Japan.

Read news story

The Japanese healthcare authorities have decided to improve reimbursement forintermittent catheters. This represents a breakthrough in the Japanese market forColoplast, who will have an easier time offering the newest and best catheters to peopleliving with incontinence in Japan.

“We already have a solid market share when it comes to our ostomy business in theJapanese market. With the new reimbursement rules in place, we see improving businessopportunities for our continence business and we will surely benefit from them,” says LarsRasmussen, CEO of Coloplast.

Coloplast has had a subsidiary in Japan for 28 years and Lars Rasmussen sees greatpotential for growth in the country going forward.

“There are close to 100,000 people in Japan living with incontinence who need a catheterand they will now have access to better and more modern products. That is very positive,”says Lars Rasmussen.

Japan generally has an advanced and very modern healthcare system, and with improvedreimbursement in place, the monthly supplement per catheter user will increase with morethan 50%.

This means better access to improved products and is a result of, among other things,Coloplast’s contribution of health economic data to the Japanese authorities.

Coloplast products are sold in more than 130 countries worldwide and Japan is animportant market in the company’s future growth plans.

 

Press enquiries

Maria Lindeberg

Senior Manager, Media Relations

Tel. +45 4911 3095

dkmalg@coloplast.com

 

Investors and financial analysts

Ian Christensen

Vice President, Investor Relations

Tel. +45 4911 1301

dkisec@coloplast.com

  • Press release
2 Feb 2016

Coloplast delivers Q1 results in line with guidance

Revenue was up by 7% to DKK 3,656 million while EBIT improved 11% for an EBIT margin of 33% in the first quarter of the 2015/16 financial year. The results were in line with the company’s expectations.

Read news story

Coloplast is off to a good start to the financial year, with most European markets showing good results and, notably, with the UK business again contributing to growth. The improvement was due in part to a solid performance by Coloplast’s own UK homecare company after an otherwise difficult year in 2014/2015.

“We’ve had a satisfactory first quarter. One of the reasons our sales have improved is because our UK company has now overcome the challenges of managing electronic prescriptions. We’re winning new and retaining existing customers in the UK market,” said Coloplast CEO Lars Rasmussen.

Sales were up by 8% in Ostomy Care, by 6% in Continence Care, 7% in Urology Care and 10% in Wound & Skin Care. In terms of sales by region, Europe was up 5%, Other Developed Markets grew 6% and Emerging Markets gained 16%.

New product well received by users
The Sensura® Mio Convex ostomy care range has been well received with highly satisfactory user feedback. For the past four months, SenSura® Mio Convex has been available in twelve countries.

“Our new Sensura Mio Convex ostomy care range will come to play a key role in the future, so it is important to us that the users like the new product,” said Mr Rasmussen.

He also mentions the Wound & Skin Care business which has performed well in recent months.

“In the European markets, the Biatain Silicone foam dressing has been the main growth driver,” said Mr Rasmussen.

Coloplast maintains its guidance for the 2015/2016 financial year of 7-8% organic revenue growth at constant exchange rates and of about 7% in DKK. The EBIT margin is expected to be 33-34% at constant exchange rates and 33% in DKK.

 

For more on the Q1 2015/16 interim report, go to www.coloplast.com/investor

 

 

Press enquiries

Dennis Kaysen

Communication Director

Tel. +45 4911 2608

dkdk@coloplast.com

 

Investors and financial analysts

Ian Christensen

Vice President, Investor Relations

Tel. +45 4911 1301

dkisec@coloplast.com

View desktop version